Cargando…

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants

Non-vitamin K antagonist oral anticoagulants (NOACs) include thrombin inhibitor dabigatran and coagulation factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and betrixaban. NOACs have several benefits over warfarin, including faster time to the achieve effect, rapid onset of action, fewer docume...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mujer, Mark Terence P., Rai, Manoj P., Atti, Varunsiri, Dimaandal, Ian Limuel, Chan, Abigail S., Shrotriya, Shiva, Gundabolu, Krishna, Dhakal, Prajwal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097770/ https://www.ncbi.nlm.nih.gov/pubmed/32231703 http://dx.doi.org/10.1155/2020/7636104

Ejemplares similares

Do USMLE steps, and ITE score predict the American Board of Internal Medicine Certifying Exam results?
por: Rayamajhi, Supratik, et al.
Publicado: (2020)

Venous Thromboembolism Risk Assessment in Hospitalized Cancer Patients: A Single Center Study
por: Rayamajhi, Supratik, et al.
Publicado: (2023)

Effectiveness of Sequential Compression Devices in Prevention of Venous Thromboembolism in Medically Ill Hospitalized Patients: A Retrospective Cohort Study
por: Dhakal, Prajwal, et al.
Publicado: (2019)

Direct oral anticoagulants (DOAC) versus vitamin K antagonist in left ventricular thrombus: An updated meta‐analysis
por: Shrestha, Dhan B., et al.
Publicado: (2023)

Pegcetacoplan in paroxysmal nocturnal hemoglobinuria: A systematic review on efficacy and safety
por: Shah, Sangam, et al.
Publicado: (2022)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
por: Faraoni, David, et al.
Publicado: (2015)

Differential Effects of Cardiac Rehabilitation in Obese and Non-Obese Population
por: Atti, Varunsiri, et al.
Publicado: (2021)

Coxsackie Myocarditis and Hepatitis with Reactivated Epstein-Bar Virus (EBV): A Case Report
por: Atti, Varunsiri, et al.
Publicado: (2017)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
por: Kustos, Stephanie A., et al.
Publicado: (2019)

Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016
por: Christos, Steve, et al.
Publicado: (2016)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Longitudinal Follow-Up of Asymptomatic COVID-19 Myocarditis with Cardiac Magnetic Resonance Imaging
por: Shotwell, Matthew K., et al.
Publicado: (2022)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Gastrointestinal bleeding during anticoagulation with direct oral anticoagulants compared to vitamin K antagonists
por: Dongre, Kanchan, et al.
Publicado: (2022)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
por: Müller, Martin, et al.
Publicado: (2019)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Oral Anticoagulants after Heart Transplantation—Comparison between Vitamin K Antagonists and Direct Oral Anticoagulants
por: Darche, Fabrice F., et al.
Publicado: (2023)

Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting
por: Dincq, Anne-Sophie, et al.
Publicado: (2014)

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with β-Thalassemia
por: Malagù, Michele, et al.
Publicado: (2023)

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus
por: Iqbal, Hansa, et al.
Publicado: (2020)

This Article Corrects: “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016”
por: Christos, Steve, et al.
Publicado: (2016)

Comparison of Left Atrial Appendage Occlusion versus Non-Vitamin-K Antagonist Oral Anticoagulation in High-Risk Atrial Fibrillation: An Update
por: Chen, Shaojie, et al.
Publicado: (2021)

Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants
por: Cullell, Natalia, et al.
Publicado: (2018)

Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants
por: Brinkmeier-Theofanopoulou, Maria, et al.
Publicado: (2018)

Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage
por: Parry‐Jones, Adrian R., et al.
Publicado: (2015)

Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist
por: Carles, Misericòrdia, et al.
Publicado: (2015)

Impact of Non-vitamin K Antagonist Oral Anticoagulant Withdrawal on Stroke Outcomes
por: Park, Joong Hyun, et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
por: Gremmel, Thomas, et al.
Publicado: (2018)

Drug–drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants
por: Mathy, François-Xavier, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis
por: Boer, Cindy G, et al.
Publicado: (2021)

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease
por: Fanaroff, Alexander C, et al.
Publicado: (2022)

Emergency Reversal of Anticoagulation
por: Yee, Jennifer, et al.
Publicado: (2019)

Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update
por: Shah, Shagun B, et al.
Publicado: (2019)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7pq74g92mt8p477mq2kjqt8j6n